e-learning
resources
ERJ
2011
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
What the pulmonary specialist should know about the new inhalation therapies
Laube B.L., Janssens H.M., de Jongh F.H.C., Devadason S.G., Dhand R., Diot P., Everard M.L., Horvath I., Navalesi P., Voshaar T., Chrystyn H.
Source:
Eur Respir J 2011; 37: 1308-1417
Journal Issue:
June
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Laube B.L., Janssens H.M., de Jongh F.H.C., Devadason S.G., Dhand R., Diot P., Everard M.L., Horvath I., Navalesi P., Voshaar T., Chrystyn H.. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37: 1308-1417
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
What the pulmonary specialist should know about the new inhalation therapies
Source: Eur Respir J 2012; 39: 1054-1055
Year: 2012
What the pulmonary specialist should know about the new inhalation therapies
Source: Guideline 2011
Year: 2011
What the pulmonary specialist should know about the new inhalation therapies
Source: Eur Respir J 2012; 39: 1055-1056
Year: 2012
Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination
Source: Annual Congress 2007 - ISAM - Expanding role of aerosols: systemic drug delivery, gene therapy and vaccination
Year: 2007
Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation
Source: Eur Respir J 2011; 38: 1328-1335
Year: 2011
Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children
Source: Eur Respir J 2003; 21: 1007-1011
Year: 2003
Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Targeting small airways in asthma: the new challenge of inhaled corticosteroid treatment
Source: Eur Respir J 2008; 31: 1145-1147
Year: 2008
Selection of the optimal nebulizer for further clinical development of inhaled nebulized nitrite (AIR001) in pulmonary arterial hypertension patients
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
When to give corticosteroid inhalation therapy in stable COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001
Reproducibility of inhaler use and pulmonary drug deposition in COPD
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Is there room for further innovation in inhaled therapy for airways disease?
Source: Breathe, 14 (3) 216; 10.1183/20734735.020318
Year: 2018
Modern treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 60S-66S
Year: 2001
The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Inhaled iloprost for the treatment of pulmonary hypertension
Source: Eur Respir Rev 2009; 18: 29-34
Year: 2009
High dose short course of inhaled corticosteroid administration may prevent home oxygen therapy in neonatal chronic lung disease
Source: Eur Respir J 2003; 22: Suppl. 45, 140s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept